Tecartus^® (brexucabtagene autoleucel): Clinical Profile & Patient Journey Guide

Tecartus was the first CAR‑T therapy approved specifically for Mantle Cell Lymphoma (MCL), addressing a significant unmet need in this aggressive B‑cell malignancy. It shares the same CD28 costimulatory domain as Yescarta, but is engineered with a distinct CD19 scFv and approved for different indications.

Tecartus is an autologous CD19‑directed CAR‑T cell therapy with a structure similar to Yescarta:

1. T‑Cell Collection: Patient's own T‑cells are collected via leukapheresis.
2. Genetic Modification: T‑cells are transduced with a retroviral vector encoding a CAR that recognizes CD19.
3. CAR Structure:
   • Targeting domain: Single‑chain variable fragment (scFv) derived from anti‑CD19 antibody
   • Costimulatory domain: CD28 (same as Yescarta), which promotes rapid T‑cell activation and potent cytotoxic response
   • Signaling domain: CD3ζ, which activates T‑cell cytotoxic function
4. Expansion: Modified cells are expanded ex vivo to achieve therapeutic doses.
5. Reinfusion: Patient receives lymphodepleting chemotherapy (fludarabine/cyclophosphamide), followed by single infusion of CAR‑T cells.
6. Mechanism: CAR‑T cells bind CD19 on B‑cells (normal and malignant), activate rapid cytotoxic response.

Mantle Cell Lymphoma (MCL) — Initial Approval July 2020

• Adult patients with relapsed or refractory mantle cell lymphoma (MCL)
• FDA label: "Adult patients with relapsed or refractory mantle cell lymphoma (MCL)"
• First CAR‑T approval specifically for MCL, addressing a population with limited treatment options

B‑Cell Acute Lymphoblastic Leukemia (B‑ALL) — Approval October 2021

• Adult patients 18 years or older with relapsed or refractory B‑cell precursor acute lymphoblastic leukemia (B‑ALL)
• FDA label: "Adult patients 18 years or older with relapsed or refractory B‑cell precursor acute lymphoblastic leukemia (ALL)"

ZUMA‑1 Trial (MCL)

• Phase II, single‑arm, multicenter study
• Adult patients with r/r MCL after prior anthracycline‑ or alkylator‑containing chemotherapy, anti‑CD20 therapy, and a BTK inhibitor
• Demonstrated high overall response rate (ORR) with durable complete responses
• Long‑term follow‑up shows sustained responses in a subset of patients
• Single‑arm study without control group

ZUMA‑2 Trial (MCL)

• Phase II, single‑arm, multicenter study
• Confirmed efficacy and safety in a larger MCL population
• Led to FDA approval for MCL indication in July 2020

ZUMA‑3 Trial (Adult B‑ALL)

• Phase I/II, single‑arm, multicenter study
• Adult patients with r/r B‑ALL after prior therapy
• Demonstrated high rates of minimal residual disease (MRD)‑negative remission
• Led to FDA approval for adult B‑ALL indication in October 2021

Tecartus carries significant safety risks that require careful patient selection and monitoring. The following are based on FDA prescribing information and clinical trial data:

(Regulatory status may change. Always verify current approval status with regional regulatory authorities.)

Pricing (Approximate, Out‑of‑Pocket for International Patients)

Total Treatment Cost Considerations

• The drug acquisition cost is only one component.
• Additional costs include:
  • Leukapheresis and cell collection
  • Lymphodepleting chemotherapy
  • Hospitalization (typically 2‑4 weeks minimum)
  • Management of CRS/ICANS (tocilizumab, corticosteroids, ICU care if needed) — may be more intensive due to CD28 construct
  • Long‑term follow‑up and monitoring
  • Immunoglobulin replacement therapy
• Total treatment episode cost can exceed $500,000‑$800,000 in the US when all components are included.

Insurance Coverage & International Access

• Coverage varies significantly by insurer, country, and specific indication.
• Many insurers require prior authorization and documentation of eligibility criteria.
• Tecartus is available only at certified treatment centers (REMS‑certified in the US or equivalent).
• Our platform can facilitate introductions to certified treatment centers, but we cannot guarantee access or coverage.

Week 0: Decision & Preparation

• Consultation with oncologist · Discussion of risks, benefits, and alternatives · Selection of certified treatment center · Insurance pre‑authorization begins

Week 1‑2: Medical Records Transfer

• Collection of complete medical history, pathology reports, imaging · Secure transfer to treatment center · Initial remote consultation

Week 3‑4: Pre‑Treatment Evaluation

• In‑person consultation · Comprehensive evaluation: cardiac, pulmonary, hepatic, renal function · Patient and caregiver education on CRS/ICANS

Week 5‑6: Leukapheresis (T‑Cell Collection)

• 4‑6 hour procedure to collect T‑cells · Cells shipped to manufacturing facility · Patient may return home or stay near treatment center

Week 7‑10: Manufacturing (Waiting Period)

• T‑cells are genetically modified, expanded, and quality‑tested · Typical manufacturing time: 3‑4 weeks · Bridging therapy if needed

Week 11: Hospital Admission & Lymphodepletion

• Admission · 3 days of lymphodepleting chemotherapy (fludarabine + cyclophosphamide) · 1‑2 day rest period

Week 12: CAR‑T Infusion

• Single intravenous infusion (typically 30‑60 minutes) · Close monitoring for immediate reactions · Day 0 of post‑infusion monitoring

Week 13‑16: Intensive Monitoring (CRS/ICANS)

• Daily vital signs, neurologic assessments · Monitoring for CRS and ICANS · Treatment with tocilizumab and/or corticosteroids if needed · Most patients remain hospitalized or very close to hospital

Week 17‑20: Discharge & Early Recovery

• Discharge if stable · Frequent outpatient follow‑up (2‑3 times per week) · Gradual return to normal activities

Month 2‑3: Continued Monitoring

• Weekly to biweekly outpatient visits · Blood tests to monitor counts, immunoglobulin levels · Imaging at day 30 and day 90

Month 4‑12: Long‑Term Follow‑Up

• Monthly visits, then every 2‑3 months · Monitoring for late effects · Annual follow‑up required for at least 15 years

What to Expect Emotionally

• Before treatment: Anxiety, hope, uncertainty are all normal
• During manufacturing: The waiting period can be especially stressful
• During CRS/ICANS: You may see confusion, personality changes, or physical symptoms — these are usually temporary
• After treatment: Adjustment period as patient recovers strength

Your Role in the Hospital

• You CAN: Provide emotional support, help with communication, assist with daily activities, advocate for patient needs
• You CANNOT: Make medical decisions (unless you have legal authority), stay in the room 24/7, replace the medical team's expertise

Preventing Caregiver Burnout

• Recognize the signs: Exhaustion, irritability, feeling overwhelmed
• Ask for help: Family, friends, hospital social workers, support groups
• Take breaks — you cannot pour from an empty cup
• Maintain your health: Sleep, nutrition, exercise

Questions You Should Ask

• What are the signs of CRS/ICANS I should watch for?
• Who do I call if there's an emergency after hours?
• What medications does the patient need to take at home?
• When can the patient return to normal activities?

"Can I have children after Tecartus?"

• The lymphodepleting chemotherapy and CAR‑T therapy may affect fertility. Discuss fertility preservation BEFORE treatment. Pregnancy after CAR‑T is possible but requires careful planning.

"Can I go back to work?"

• Most patients need 2‑3 months off work minimum. Return depends on recovery, blood counts, cognitive function, and energy levels.

"What if the treatment doesn't work?"

• Options may include other CAR‑T products, clinical trials, stem cell transplant, other targeted therapies, or palliative care. Having a backup plan can reduce anxiety.

"Does CAR‑T hurt?"

• Leukapheresis is generally well‑tolerated. The infusion itself is usually painless. Chemotherapy and CRS can cause side effects, but these are managed with medications.

"How long will I be away from home?"

• If local: 4‑6 weeks minimum. If traveling internationally: plan for 2‑3 months away from home including recovery.

"Can I get vaccinated after CAR‑T?"

• Live vaccines are avoided for at least 6 weeks before and 6 months after CAR‑T. Inactivated vaccines may be given after immune recovery (typically 3‑6 months post‑treatment).

Why Might Tecartus Not Work?

• Antigen escape: Cancer cells may lose CD19 expression
• Insufficient CAR‑T expansion: Not enough CAR‑T cells persist
• Disease too advanced: Very high tumor burden may overwhelm the response
• Patient factors: Poor performance status, organ dysfunction

What Are the Next Options?

• Other CAR‑T products targeting different antigens (BCMA, CD22)
• Clinical trials with new constructs or bispecific antibodies
• Allogeneic stem cell transplant
• Palliative care focusing on quality of life

Wait times can be longer if manufacturing delays occur. International patients must factor in travel, accommodation, and extended stay costs. Not all patients are eligible — performance status, organ function, and disease characteristics must meet criteria.

These are general pharmacological differences. Individual patient responses vary. Treatment selection should be based on specific clinical circumstances, disease characteristics, and physician recommendation.